DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021" report to their offering.
The influenza diagnostics market is expected to reach USD 767.4 Million by 2021 from USD 508.0 Million in 2016, at a CAGR of 8.6% from 2016 to 2021.
The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza are the major factors that are expected to drive the growth of this market in the coming years. However, variability in sensitivity and specificity among influenza diagnostic tests, presence of a complex regulatory framework for the approval of new diagnostic tests, and rising healthcare costs are expected to restrain the growth of this market to a certain extent in the coming years.
This report segments the global influenza diagnostics market on the basis of test type, end user, and region. On the basis of test type, the market is segmented into traditional and molecular diagnostic tests.
The traditional diagnostic tests segment is further categorized into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. In 2016, the RIDT segment is expected to account for the largest share of the traditional diagnostic tests market owing to factors such as its user-friendliness, rapid generation of results, and easy interpretability.
The molecular diagnostic tests segment is further categorized into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), and simple amplification-based assays (SAMBA). In 2016, the RT-PCR segment is expected to hold the largest share of the molecular diagnostic tests market due to its ability to detect and distinguish between influenza A and B viruses with high specificity.
- Increasing Prevalence of Influenza
- Growth in Research Funding for Influenza Diagnostics
- Rising Demand for Faster Diagnosis And Control of Influenza
- Variability in Sensitivity And Specificity Among Influenza Diagnostic Tests
- Stringent Regulatory Framework
- Rising Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques
- Advancements in Genomic And Proteomic Technologies
- Significant Growth Prospects in Developing Countries
- Dearth of Skilled Personnel to Handle Advanced Influenza Diagnostic Tools
- Alere Inc.
- Analytik Jena Ag (A Subsidiary of Endress+Hauser Ag)
- Becton, Dickinson And Company
- Diasorin S.P.A.
- F. Hoffmann-La Roche Ag
- Luminex Corporation
- Meridian Bioscience, Inc.
- Quidel Corporation
- SA Scientific, Ltd.
- Thermo Fisher Scientific Inc.
For more information about this report visit http://www.researchandmarkets.com/research/cxbldc/influenza